10 results about "Pertuzumab" patented technology

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

To provide uses of pertuzumab, which is a first in-class HER2 dimerization inhibitors, and articles of manufacture comprising the same.SOLUTION: A method for extending progression free survival in a population of HER2 + breast carcinoma patients; a method for combining two HER2 antibodies to treat HER2 + breast carcinoma without increasing cardiotoxicity; a method for treating early HER2 + breast carcinoma; a method for treating HER2 + breast carcinoma by co-administering a mixture of pertuzumab and trastuzumab from the same I. v. bag; a method for treating HER2 + metastatic gastric carcinoma; a method for treating HER2 + breast carcinoma with pertuzumab, trastuzumab and vinorelbine; Methods for treating HER2 positive breast cancers with trastuzumab and aromatase inhibitors; and methods for treating low HER3 ovarian, primary peritoneal, or fallopian tube cancers are provided.SELECTED DRAWING: None

Combination therapy comprising inalipase and a fixed-dose combination (PH FDC SC) of pertuzumab and trastuzumab for subcutaneous injection is provided for the treatment of HER2-positive cancer; and a method for treating PIK3CA-mutated HER2-positive (HER2+) locally advanced or metastatic breast cancer, the method comprising administering a therapeutically effective amount of inalipase and PH FDC SC.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

The application provides an anti-HER2 nanobody and a preparation method and application thereof. Specifically, the application also provides a corresponding anti-HER2 antibody, a chimeric antigen receptor, a fusion protein, a recombinant protein and nucleic acid coding same, an expression vector, a host cell and the like. The anti-HER2 nanobody of the application has high affinity, simple structure, is easy to prepare, and is different from the antigen epitope combined by trastuzumab and pertuzumab, and has a wide application prospect in the fields of tumor treatment, immune detection and the like.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The application belongs to the field of biological medicine, and particularly relates to a HER2 antibody, a pharmaceutical composition and application thereof. The application provides an antibody binding to HER2, which comprises a first antigen binding part and a second antigen binding part, the first antigen binding part comprises an anti-HER2 nanobody, and the sequence of the anti-HER2 nanobody comprises an amino acid sequence as shown in any one of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8, and the second antigen binding part comprises trastuzumab or pertuzumab. The antibody provided by the application has the effect of inhibiting HER2 related tumors, the bispecific antibody in the antibody can specifically recognize different epitopes of HER2, inhibit non-ligand dependent and ligand dependent HER2 positive tumor cell proliferation, has obvious inhibiting effect on HER2 positive tumors and HER2 low expression tumors resistant to trastuzumab, and provides a new scheme for diagnosis and treatment of HER2 related tumors.

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.